International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

被引：121

作者：

Lokhorst, Henk

Einsele, Hermann

Vesole, David

Bruno, Benedetto

Miguel, Jesus San

Perez-Simon, Jose A.

Kroger, Nicolaus

Moreau, Philippe

Gahrton, Gosta

Gasparetto, Cristina

Giralt, Sergio

Bensinger, William

机构：

[1] Univ Utrecht Hosp, Utrecht, Netherlands

[2] Univ Hosp Wuerzburg, Wurzburg, Germany

[3] Univ Hosp Hamburg Eppendorf, Hamburg, Germany

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Turin, Giovanni Battista Hosp, Turin, Italy

[6] Univ Hosp Salamanca, Salamanca, Spain

[7] Ctr Hosp Univ Hotel Dieu, Nantes, France

[8] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden

[9] Duke Univ Hosp, Durham, NC USA

[10] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期

关键词：

VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; IN-SITU HYBRIDIZATION; TANDEM AUTOLOGOUS TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; COOPERATIVE-ONCOLOGY-GROUP; NEWLY-DIAGNOSED MYELOMA; HIGH-DOSE CHEMOTHERAPY; RELAPSE-FREE SURVIVAL;

D O I：

10.1200/JCO.2010.29.7929

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology

引用

页码：4521 / 4530

页数：10

共 107 条

[21] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].

Chang, H ;

Qi, C ;

Yi, QL ;

Reece, D ;

Stewart, AK .

BLOOD, 2005, 105 (01) :358-360

[22] Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma [J].

Corradini, P ;

Cavo, M ;

Lokhorst, H ;

Martinelli, G ;

Terragna, C ;

Majolino, I ;

Valagussa, P ;

Boccadoro, M ;

Samson, D ;

Bacigalupo, A ;

Russell, N ;

Montefusco, V ;

Voena, C ;

Gahrton, G .

BLOOD, 2003, 102 (05) :1927-1929

[23] Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT [J].

Crawley, C ;

Lalancette, M ;

Szydlo, R ;

Gilleece, M ;

Peggs, K ;

Mackinnon, S ;

Juliusson, G ;

Ahlberg, L ;

Nagler, A ;

Shimoni, A ;

Sureda, A ;

Boiron, JM ;

Einsele, H ;

Chopra, R ;

Carella, A ;

Cavenagh, J ;

Gratwohl, A ;

Garban, F ;

Zander, A ;

Björkstrand, B ;

Niederwieser, D ;

Gahrton, G ;

Apperley, JF .

BLOOD, 2005, 105 (11) :4532-4539

[24] Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning [J].

Crawley, Charles ;

Iacobelli, Simona ;

Bjorkstrand, Bo ;

Apperley, Jane F. ;

Niederwieser, Dietger ;

Gahrton, Gosta .

BLOOD, 2007, 109 (08) :3588-3594

[25] Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma [J].

de Donk, N. W. C. J. van ;

Kroeger, N. ;

Hegenbart, U. ;

Corradini, P. ;

Miguel, J. F. San ;

Goldschmidt, H. ;

Perez-Simon, J. A. ;

Zijlmans, M. ;

Raymakers, R. A. ;

Montefusco, V. ;

Ayuk, F. A. ;

van Oers, M. H. J. ;

Nagler, A. ;

Verdonck, L. F. ;

Lokhorst, H. M. .

BONE MARROW TRANSPLANTATION, 2006, 37 (12) :1135-1141

[26]

Durie BG, 1995, P AN M AM SOC CLIN, V15, P405

[27] Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning [J].

Einsele, H ;

Schäfer, HJ ;

Hebart, H ;

Bader, P ;

Meisner, C ;

Plasswilm, L ;

Liebisch, P ;

Bamberg, M ;

Faul, C ;

Kanz, L .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) :411-418

[28] High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma [J].

El-Cheikh, Jean ;

Michallet, Mauricette ;

Nagler, Arnon ;

de Lavallade, Hugues ;

Nicolini, Franck E. ;

Shimoni, Avichai ;

Faucher, Catherine ;

Sobh, Mohamad ;

Revesz, Daniela ;

Hardan, Izhar ;

Furst, Sabine ;

Blaise, Didier ;

Mohty, Mohamad .

HAEMATOLOGICA, 2008, 93 (03) :455-458

[29] Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy [J].

Facon, T ;

Avet-Loiseau, H ;

Guillerm, G ;

Moreau, P ;

Geneviève, F ;

Zandecki, M ;

Laï, JL ;

Leleu, X ;

Jouet, JP ;

Bauters, F ;

Harousseau, JL ;

Bataille, R ;

Mary, JY .

BLOOD, 2001, 97 (06) :1566-1571

[30] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

← 1 2 3 4 5 6 7 8 9 10 →